Who is sponsoring NCT04059887?

NCT04059887 is sponsored by Chonnam National University Hospital.

What drugs are being tested in NCT04059887?

Interventions in NCT04059887: Atezolizumab Injection [Tecentriq].

What condition does NCT04059887 study?

NCT04059887 studies Lung Neoplasm Malignant.

Is NCT04059887 still recruiting?

NCT04059887 is currently completed. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT04059887: BUDDY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]

Completed Phase 4 Last updated 8 February 2023

What this trial tests

Phase 4 trial testing Atezolizumab Injection [Tecentriq] in Lung Neoplasm Malignant in 100 participants. Completed in 30 June 2022.

Timeline

18 December 2019

Primary endpoint
31 December 2021

30 June 2022

Quick facts

Lead sponsor	Chonnam National University Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	18 December 2019
Primary completion	31 December 2021
Estimated completion	30 June 2022
Sites	1 location across South Korea

Drugs / interventions tested

Atezolizumab Injection [Tecentriq] — full drug profile →

Conditions studied

Lung Neoplasm Malignant — all drugs for Lung Neoplasm Malignant →

Sponsor

Chonnam National University Hospital

Who can join

18 and older, any sex, with Lung Neoplasm Malignant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is single arm, prospective, multi-center, cohort study to evaluate blood TMB for improved efficacy of atezolizumab in locally advanced or metastatic NSCLC at the study enrollment who failed one or more prior lines of chemotherapy including at least 1 platinum-based.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A, Mohammed RN, Raji A, Chupradit S, et al · · 2022 · cited 350× · PMID 35392976 · DOI 10.1186/s12964-022-00854-y
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy.
Anagnostou V, Landon BV, Medina JE, Forde P, et al · · 2022 · cited 38× · PMID 36350985 · DOI 10.1126/scitranslmed.abo3958
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.
Ancel J, Dormoy V, Raby BN, Dalstein V, et al · · 2023 · cited 24× · PMID 37283751 · DOI 10.3389/fimmu.2023.1171649
Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies.
Ahmed J, Das B, Shin S, Chen A. · · 2023 · cited 22× · PMID 38136385 · DOI 10.3390/cancers15245841

Verify or expand the search:

Other recruiting trials for Lung Neoplasm Malignant

Currently open trials in the same condition.

NCT07286149 — A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) · Phase 1, PHASE2 · recruiting
NCT07071103 — Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors · Phase 2 · recruiting
NCT06788912 — Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAK · Phase 2 · recruiting
NCT06440616 — Benefit of Spectral Information in Patients Suspected for Lung Cancer · NA · recruiting
NCT06079970 — Confocal Laser Endomicroscopy VERification · NA · recruiting

Other Chonnam National University Hospital trials

Trials by the same sponsor.

NCT07390461 — Effectiveness of Artificial Intelligence Integrated Mixed Reality-based High-Alert Medications Management Simulation Pro · NA · not yet recruiting
NCT07482228 — Long-term Clinical Outcomes After Retinal Artery Occlusion · recruiting
NCT06954714 — Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions · NA · recruiting
NCT07002164 — Timing of Coronary Angiography in NSTEMI Complicated by Acute HF · NA · recruiting
NCT06227754 — OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04059887 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chonnam National University Hospital
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04059887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing